Originally published Oct. 28.

NEW YORK (GenomeWeb) – Arno Therapeutics recently presented data from an ongoing Phase I/II dosing trial involving its lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC).

In CRPC, Arno is conducting a randomized Phase I/II open label trial looking at five doses (10 mg to 50 mg twice daily) of onapristone. The hormone blocker is Arno's lead product and is designed to block activation of the progesterone receptor that many tumors depend on to grow and advance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.